Biomarker Testing Optimizes Therapy Choice in Advanced NSCLC

Patients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed.

Related Keywords

United States , Massachusetts , American , Adamc Powell , , American Society Of Clinical Oncology , Provider Syndicate , National Comprehensive Cancer Network , Journal Of The National Comprehensive Cancer Network , American Society , Clinical Oncology , National Comprehensive Cancer , Lung Cancer , Ung Carcinoma , Ancer Of The Lung , Non Small Cell Lung Cancer , Nsclc , Biomarker , Iological Marker , Ulti Biomarker Disease Activity , Bda , Multibiomarker Disease Activity , Genomics Genomic Medicine , Small Cell Lung Cancer , At Cell Lung Cancer , Clc , Biologic Therapy , Iologics , Otolaryngology , Nt Specialty , Ead And Neck Surgery Ent Speciality , Cancer ,